Israeli pharmaceutical concern «Teva» was expelled in the second quarter of 2017 6.1 billion to cover the declining value of the investment in genernal Department of the company Allergan.
The company has cut $ 700 million profit forecast for 2017 and 75% reduction in dividends.
The company’s revenues in the second quarter amounted to $ 5.7 billion, which is 13% higher than the same period last year. At the same time, gross profit decreased by 2%.
Immediately after the publication of the report for the second quarter of the company’s management announced its intention before the end of 2017 to leave the markets of 45 countries, and by the end of 2018 to close or sell 15 plants and cut staff by 7,000 employees.
The group has also hired consultants to optimize the portfolio of medicines sold.
We will remind that earlier it became known that the new York court rejected the claim of the Israeli pharmaceutical company «Teva» on the fraud by the former owners of the company Rimasa in the amount of 2.3 billion dollars.
To discuss visit NEWSru.co.il in Facebook